Novel Drug Shows a Signal to Improve nHCM Novel Drug Shows a Signal to Improve nHCM
In the phase 2 IMPROVE-HCM trial, cardiac mitotrope ninerafaxstat was safe, with a signal of improved cardiac function in moderate nonobstructive hypertrophic cardiomyopathy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 12, 2024 Category: Cardiology Tags: Cardiology News Source Type: news
How to Talk to Your Family About Their Heart Health History
Hypertrophic obstructive cardiomyopathy (HOCM) is the most common genetic heart disease, affecting about 1 in every 500 people, according to the American Heart Association (AHA). In people with HOCM, genetic variants cause the heart’s walls to thicken and stiffen, blocking blood from flowing freely from the left ventricle to the aorta. This, in turn, results in shortness of breath and chest pain (especially during physical activity), abnormal heart rhythms, lightheadedness, dizziness, and fainting, and can worsen over time.
[time-brightcove not-tgx=”true”]
If a parent has HOCM, offspring have a 50% ch...
Source: TIME: Health - April 11, 2024 Category: Consumer Health News Authors: Sarah Klein Tags: Uncategorized Evergreen freelance healthscienceclimate Source Type: news
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 …
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE…#primaryresults #incorporatedcytk #sequoiahcm #efficacy #phase3 #hcm #heartfailure #lisbon #portugal #martinmaron (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2024 Category: Consumer Health News Source Type: news
How Hypertrophic Cardiomyopathy Progresses in Adults
Hypertrophic cardiomyopathy is the most common form of genetic heart disease worldwide. Researchers have estimated that up to 1 in 200 people have the condition, which is characterized by an abnormal thickening of the walls of the heart. This thickening can make it difficult for the heart to pump blood.
Hypertrophic cardiomyopathy can be a deadly disease, and there was a time when it was largely untreatable. But the last 20 years have witnessed a sea change in the condition’s management—a change that has led to an estimated 10-fold decrease in deaths.
[time-brightcove not-tgx=”true”]
“...
Source: TIME: Health - March 27, 2024 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized freelance healthscienceclimate Source Type: news
CT-FFR shows how smoking affects heart volume-to-myocardial mass ratio
Both current and former smokers show lower coronary volume-to-myocardial mass ratio (V/M) on CT fractional flow reserve (CT-FFR), researchers have found.
In a study published March 14 in Radiology: Cardiothoracic Imaging, a team led by Kenneth Holmes, MD, of St Paul's Hospital and University of British Columbia in Vancouver, Canada, reported that smoking was associated with lower coronary volume-to-myocardial mass ratio in individuals with coronary artery disease (CAD) -- results that further cement the link between smoking and heart disease.
"[We found that] current and former smoking were independently associated with ...
Source: AuntMinnie.com Headlines - March 14, 2024 Category: Radiology Authors: Kate Madden Yee Tags: Clinical News CT Cardiovascular Radiology Source Type: news
Dead lifts and death: sudden death due to hypertrophic cardiomyopathy in a body builder - Gupta R, Dsouza HL, Rai S, Shetty P, Rastogi P, Pp JR.
BACKGROUND: It is a well established fact that cardiac health and exercise go hand in hand.However, rigorous exercising regimens without proper cardiovascular screening can lead to catastrophic death in unsuspecting and otherwise healthy individuals. Among... (Source: SafetyLit)
Source: SafetyLit - March 4, 2024 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Viewpoint Collaborates with TriviumVet for Special Educational Episode on Feline Hypertrophic Cardiomyopathy and Pet Wellbeing
The educational program highlights a specific condition in cats... MIAMI, Feb. 22, 2024 /PRNewswire-PRWeb/ -- Renowned actor and host, Dennis Quaid, hosts the program Viewpoint, who have joined forces with TriviumVet to present an enlightening and educational episode centered around... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 22, 2024 Category: Pharmaceuticals Tags: PET Source Type: news
Mayo Clinic Minute: Know the warning signs of hypertrophic cardiomyopathy
It's often silent but can be a deadly killer. Hypertrophic cardiomyopathy is a genetic condition that occurs in 1 in 500 people. Dr. Said Alsidawi, a Mayo Clinic cardiologist, says the problem is that many people don't even know they have it because they have no symptoms. And in 20% of cases, the first presentation is sudden cardiac death. Watch: The Mayo Clinic Minute https://youtu.be/M6RrnuAc_1M Journalists: Broadcast-quality video (1:07) is in the downloads at the… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 20, 2024 Category: Databases & Libraries Source Type: news
How This Top 2% Biotech Overcame Two Obstacles And Doubled In A Month
has shucked off two high-profile setbacks, leading CYTK stock to double over a month as it looks to take on Big Pharma behemoth Bristol Myers Squibb (BMY) in heart disease treatment. Bristol Myers and Squibb are working to treat obstructive hypertrophic cardiomyopathy, or HCM, a genetic mutation…#bristolmyerssquibb #bmy #bristolmyers #squibb #hcm #cytokinetics #ubs #ashwaniverma #nvs #robertblum (Source: Reuters: Health)
Source: Reuters: Health - February 10, 2024 Category: Consumer Health News Source Type: news
Reduced Blood Lead Levels Linked to Lower Blood Pressure in American Indians
Researchers have linked a decade-long decline in the blood lead levels of American Indian adults to long-term cardiovascular health benefits, including reduced blood pressure levels and a reduction in a marker associated with hypertrophic cardiomyopathy and heart failure. (Source: NIEHS News)
Source: NIEHS News - January 11, 2024 Category: Environmental Health Source Type: news
Positive Topline Results for SEQUOIA-HCM Trial in OHCM Positive Topline Results for SEQUOIA-HCM Trial in OHCM
Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 28, 2023 Category: Cardiology Tags: Cardiology Source Type: news
What to Know About Hypertrophic Cardiomyopathy in Kids
The human heart is a muscle, but it’s also a kind of complicated balloon—a balloon that fills and empties roughly 60 to 100 times every minute, and several billion times during the course of a lifetime.
Among people with hypertrophic cardiomyopathy, the walls of the heart muscle are abnormally thick. This thickness can interfere with the heart’s normal filling-and-emptying operation. “If you think of a balloon made with super-thick rubber, you have to blow harder to fill it, and it’s the same with a hypertrophic heart,” says Dr. Daphne Hsu, professor of pediatrics and medicine at Ped...
Source: TIME: Health - November 2, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized freelance healthscienceclimate Source Type: news
Base Pair Bio Receives Grant from NIH to Help Deliver Therapies for Genetic Heart Disease
Base Pair Biotechnologies, "The Aptamer Discovery Company™" has been recently awarded a grant from NIH entitled, "Aptamer engineering of lentiviral vectors for cardiac gene therapies". HOUSTON, Sept. 27, 2023 /PRNewswire-PRWeb/ -- Hypertrophic cardiomyopathy (HCM) is the leading cause of... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 28, 2023 Category: Pharmaceuticals Source Type: news
ESC Issues First Comprehensive Cardiomyopathy Guidelines ESC Issues First Comprehensive Cardiomyopathy Guidelines
The European Society of Cardiology has released the first major set of international guidelines to address cardiomyopathies beyond hypertrophic forms.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - September 1, 2023 Category: Internal Medicine Tags: Cardiology News Source Type: news
ESC: Mavacamten Cuts Need for Septal Reduction Tx with Hypertrophic Cardiomyopathy
TUESDAY, Aug. 29, 2023 -- In patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), mavacamten reduces the need for septal reduction therapy (SRT) at week 56, according to a study published online Aug. 28 in JAMA Cardiology to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 29, 2023 Category: Pharmaceuticals Source Type: news
